bioMérieux finalizes full acquisition of BioFire

bioMérieux, a vitro diagnostics company, announced on Thursday that it has finalized its full ownership of BioFire Diagnotics. Inc., a privately-held company that specializes in molecular biology.

BioFire was established more than 20 years ago and is known for its PCR molecular biology systems. BioFire recently developed the Film Array, which includes two CE-marked and FDA-cleared panels, the Respiratory Panel and the Blood Culture Identification Panel, which combine all steps in molecular diagnostics - amplification, detection, sample preparation and analysis - into one easy-to-use system.

bioMérieux plans to use its franchise in diagnostics of infectious diseases to help market the FilmArray. bioMérieux also plans to enhance its automation of reagent production for the FilmArray to help reduce manufacturing costs.

"We are pleased to see both companies join forces to enrich FilmArray's menu and to reach new customers with a global sales and marketing force," BioFire Chief Executive Officer and Founder Kirk Ririe said. "The legacy of what we have built at BioFire is the result of the contributions of so many talented individuals and we are tremendously excited about our prospects under the stewardship of bioMérieux, a company similarly committed to improving patient care worldwide."

bioMérieux and BioFire will begin company integration immediately to help expand the menu and sales of FilmArray. A wholly-owned subsidiary of BioFire will also be dedicated to biodefense capabilities to meet the demand of BioFire's existing customer base. All BioFire employees, activities and equipment related to defense are expected to be relocated to Salt Lake City.